Handelsavisen
prelaunch
Companies ›Healthcare ›300705.SZ
30
300705.SZ — Shenzhen Stock Exchange Pharmaceuticals

Hunan Jiudian Pharmaceutical Co Ltd

¥11,77
Open in Charts → Attach watcher ⌖
— —
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
5,9B CNY
P/E
—
EV / Rev
—
Div yield
2,44 %
Op margin
17,2 %
ROE
17,8 %
Net margin
15,2 %
Debt / equity
0,25
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Hunan Jiudian Pharmaceutical Co Ltd is a pharmaceutical company that develops, produces, and sells a range of pharmaceutical products, primarily in the Chinese market.

Business. Hunan Jiudian Pharmaceutical Co Ltd (300705.SZ) is a pharmaceutical company headquartered in China that operates within the healthcare sector. The firm is primarily engaged in the development and sale of pharmaceutical products. It is listed on the Shenzhen Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
17,8 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 300705.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 300705.SZ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Hunan Jiudian Pharmaceutical Co Ltd (300705.SZ) is a pharmaceutical company headquartered in China that operates within the healthcare sector. The firm is primarily engaged in the development and sale of pharmaceutical products. It is listed on the Shenzhen Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    Hunan Jiudian Pharmaceutical Co Ltd maintains a relatively strong liquidity position, with a current ratio of 3.64, indicating that it has sufficient current assets to cover its current liabilities. However, the company reported negative net cash after subtracting total debt, which raises some liquidity concerns. The company's price-to-book ratio is 2.21, and its price-to-tangible-book ratio is also 2.21, suggesting that the market values the company at a premium to its book value.

    In terms of profitability, the company's return on equity (ROE) is 17.78%, and its return on assets (ROA) is 11.77%, both of which are strong indicators of efficient use of equity and assets. The company's gross profit margin is 72.7%, and its operating margin is 17.1%, which are both above the industry median for pharmaceutical companies.

    The company's revenue is primarily concentrated in its domestic market, with no significant international revenue disclosed in the latest financial data. Hunan Jiudian Pharmaceutical Co Ltd operates as a single business segment, and its geographic exposure is primarily within China.

    Looking ahead, the company's revenue is expected to grow in the current fiscal year, with a positive outlook for the next fiscal year as well. However, the company's free cash flow is negative, at -218.68 million CNY, which may limit its ability to fund growth initiatives without external financing. The company's capital expenditure of -652.89 million CNY indicates a significant investment in long-term assets.

    The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio is 0.25, indicating a relatively conservative capital structure. However, the negative net cash position after subtracting total debt suggests that the company may need to raise additional capital in the near term. No dilution sources were identified in the latest filings or transcripts.

    Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's latest financial results were released in the most recent quarter, and no significant earnings surprises or regulatory actions were reported.

    Key takeaways
    • Hunan Jiudian Pharmaceutical Co Ltd has a strong ROE of 17.78% and ROA of 11.77%, indicating efficient use of equity and assets.
    • The company's liquidity position is strong, with a current ratio of 3.64, but its net cash position is negative after subtracting total debt.
    • The company's price-to-book ratio of 2.21 suggests that the market values the company at a premium to its book value.
    • Hunan Jiudian Pharmaceutical Co Ltd's revenue is primarily concentrated in its domestic market, with no significant international exposure.
    • The company's free cash flow is negative, which may limit its ability to fund growth initiatives without external financing.
    • The company's risk profile is characterized by a medium liquidity risk and a low dilution risk.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥11,77
    Market cap
    ¥5.89B
    Enterprise valueⓘ
    ¥6.54B
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    10.1x
    P / Bⓘ
    2.2x
    P / Tangible bookⓘ
    2.2x
    Tangible book
    ¥2.66B
    Net cashⓘ
    -¥653.1M
    Current ratioⓘ
    3.6
    Debt / equityⓘ
    0.2
    ROAⓘ
    11.8%
    ROEⓘ
    17.8%
    Cash conversionⓘ
    137.0%
    CapEx / revenueⓘ
    -21.0%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin17,2 %Above P75
    Net Margin15,2 %Above P75
    ROE17,8 %Above P75
    Capex / Rev-21,0 %Bottom quartile
    D/E0,25Below median
    Cash Conv1,37Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • Hunan Jiudian Pharmaceutical Co Ltd Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    300705.SZCanonical
    Shenzhen Stock Exchange · CNY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage